Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat

British Journal of Pharmacology

Volumn 150, Issue 5, 2007, Pages 567-576

  Rossoni, G ^a   Manfredi, B ^a   De Gennaro Colonna, V ^a   Berti, M ^a   Guazzi, M ^a   Berti, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

L NAME induced hypertension; Myocardial ischaemia reperfusion; Sildenafil

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; 8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLCHOLINE; CREATINE KINASE; CYCLIC GMP; DRINKING WATER; LACTATE DEHYDROGENASE; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE; NITRITE; NORADRENALIN; SILDENAFIL; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART PROTECTION; HEART VENTRICLE FUNCTION; HYPERTENSION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SYSTOLIC BLOOD PRESSURE; URINALYSIS; VASCULAR RING; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CYCLIC GMP; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HEART RATE; HYPERTENSION; MALE; MYOCARDIAL REPERFUSION INJURY; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; SULFONES; TIME FACTORS; VASODILATION; VASODILATOR AGENTS; VENTRICULAR FUNCTION;

EID: 33847686720     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707131     Document Type: Article

References (41)

1. Bergmeyer HU, Rich W, Butter H, Schmidt E, Hillman G, Kreuz FH et al. (1970). Standardization of methods for estimation of enzyme activity in biological fluids. Z Klin Chem Klin Biochem 8: 658-660.
2. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF (2002). Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 106: 1097-1103.
3. Du Toit EF, Rossouw E, Salie R, Opie LH, Lochner A (2005). Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. Cardiovasc Drugs Ther 19: 23-31.
4. Duarte J, Jimenez R, O'Valle F, Galisteo M, Perez-Palencia R, Vargas F et al. (2002). Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats. J Hypertens 20: 1843-1854.
5. Feenstra J, van Drie-Pierik RJ, Lacle CF, Stricker BH (1998). Acute myocardial infarction associated with sildenafil. Lancet 352: 957-958.
6. Ferreira-Melo SE, Yugar-Toledo JC, Coelho OR, De Luca IM, Tanus-Santos JE, Hyslop S et al. (2006). Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. Eur J Pharmacol; 542: 141-147.
7. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC (2005). Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111: 1601-1610.
8. Giordano D, De Stefano ME, Citro G, Modica A, Giorgi M (2001). Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 1539: 16-27.
9. Gresser U, Gleiter CH (2002). Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature. Eur J Med Res 7: 435-446.
10. Griendling KK, Alexander RW (1997). Oxidative stress and cardiovascular disease. Circulation 96: 3264-3265.
11. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD (2004). The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 44: 2339-2348.
12. Hassan MA, Ketat AF (2005). Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 5: 10-16.
13. Henry PD, Schuchleib R, Davis J, Weiss ES, Sobel BE (1977). Myocardial contracture and accumulation of mitochondrial calcium in ischemic rabbit heart. Am J Physiol 233: H677-H684.
14. Hohorst HJ (1963). L-(+)-lactate. In: Bergmeyer HU (ed). Methods of Enzymatic Analysis. Academic Press Inc.: New York, pp 215-219.
15. Kai H, Kanaide H, Matsumoto T, Nakamura M (1987). 8-bromoguanosine 3′:5′-cyclic monophosphate decreases intracellular free calcium concentrations in cultured vascular smooth muscle cells from rat aorta. FEBS Lett 221: 284-288.
16. Kloner RA (2000). Cardiovascular risk and sildenafil. Am J Cardiol 86: 57F-61F.
17. Liu Y, Tsuchihashi T, Kagiyama S, Matsumura K, Abe I, Fujishima M (1998). Central and peripheral mechanisms involved in hypertension induced by chronic inhibition of nitric oxide synthase in rats. J Hypertens 16: 1165-1173.
18. Lowry OH, Rosenbrough NT, Farr AL, Randall RJ (1951). Protein measurements with the Folin phenol reagent. J Biol Chem 193: 265-275.
19. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA 88: 1197-1201.
20. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S (2002). Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105: 2398-2403.
21. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH (1998). Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 10: 69-73.
22. Moreland RB, Goldstein I, Traish A (1998). Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 62: PL309-PL318.
23. ATP channels in rabbits. Am J Physiol Heart Circ Physiol 283: H1263-H1269.
24. Ortiz MC, Manríquez MC, Romero JC, Juncos LA (2001). Antioxidant block angiotensin II-induced increases in blood pressure and endothelin. Hypertension 38: 655-659.
25. Pechanova O, Bernatova I, Babal P, Martinez MC, Kysela S, Stvrtina S et al. (2004). Red wine polyphenols prevent cardiovascular alterations in L-NAME-induced hypertension. J Hypertens 22: 1551-1559.
26. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ (1993). Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 21: 660-666.
27. Porstmann T, Kiessing ST (1992). Enzyme immunoassay techniques. An overview. J Immunol Methods 150: 5-21.
28. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R (1992). Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20: 298-303.
29. Rossoni G, Berti F, Bernareggi M, Villa L, Agozzino S, Cereda R et al. (1995). Protective effects of ITF 296 in the isolated rabbit heart subjected to global ischemia. J Cardiovasc Pharmacol 26: S44-S52.
30. Rossoni G, Berti M, De Gennaro Colonna V, Bernareggi M, Del Soldato P, Berti F (2000). Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vivo and in vitro experiments in the rabbit. Ital Heart J 1: 146-155.
31. Rossoni G, De Gennaro Colonna V, Bernareggi M, Polvani GL, Muller EE, Berti F (1998). Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. J Cardiovasc Pharmacol 32: 260-265.
32. Rossoni G, Manfredi B, Del Soldato P, Berti F (2004). The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. J Pharmacol Exp Ther 310: 555-562.
33. Salloum F, Yin C, Xi L, Kukreja C (2003). Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in the mouse heart. Circ Res 92: 595-597.
34. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A et al. (2001). Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 15: 1718-1726.
35. 2 receptor. J Clin Invest 90: 136-141.
36. Teixeira CE, Priviero FB, Webb RC (2006). Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 316: 654-661.
37. 2α formation in L-NAME-treated rats. J Hypertens 21: 601-609.
38. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ (1999). Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 84: 1020-1031.
39. Virag R, Bouilly P, Frydman D (1985). Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1: 181-184.
40. Wallis RM, Corbin JD, Francis SH, Ellis P (1999). Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83: 3C-12C.
41. Wysowski DK, , Farinas E, Swartz L (2002). Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 89: 1331-1334.